1
|
Lomonosova E and Chinnadurai G: BH3-only
proteins in apoptosis and beyond: An overview. Oncogene. 27 Suppl
1:S2–S19. 2008. View Article : Google Scholar : PubMed/NCBI
|
2
|
Shamas-Din A, Brahmbhatt H, Leber B and
Andrews DW: BH3-only proteins: Orchestrators of apoptosis. Biochim
Biophys Acta 1813. 508–520. 2011.
|
3
|
Ghiotto F, Fais F and Bruno S: BH3-only
proteins: The death-puppeteer's wires. Cytometry A. 77:11–21.
2010.PubMed/NCBI
|
4
|
Luo Y, Wang X, Wang H, Xu Y, Wen Q, Fan S,
Zhao R, Jiang S, Yang J, Liu Y, et al: High Bak expression is
associated with a favorable prognosis in breast cancer and
sensitizes breast cancer cells to paclitaxel. PLoS One.
10:e1389552015. View Article : Google Scholar
|
5
|
Birkinshaw RW and Czabotar PE: The BCL-2
family of proteins and mitochondrial outer membrane
permeabilisation. Semin Cell Dev Biol. 72:152–162. 2017. View Article : Google Scholar : PubMed/NCBI
|
6
|
Yu X, Li Z and Shen J: BRD7: A novel tumor
suppressor gene in different cancers. Am J Transl Res. 8:742–748.
2016.PubMed/NCBI
|
7
|
Liu Y, Zhao R, Wang H, Luo Y, Wang X, Niu
W, Zhou Y, Wen Q, Fan S, Li X, et al: miR-141 is involved in
BRD7-mediated cell proliferation and tumor formation through
suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma.
Cell Death Dis. 7:e21562016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Chen CL, Wang Y, Pan QZ, Tang Y, Wang QJ,
Pan K, Huang LX, He J, Zhao JJ, Jiang SS, et al:
Bromodomain-containing protein 7 (BRD7) as a potential tumor
suppressor in hepatocellular carcinoma. Oncotarget. 7:16248–16261.
2016.PubMed/NCBI
|
9
|
Zhang Q, Wei L, Yang H, Yang W, Yang Q,
Zhang Z, Wu K and Wu J: Bromodomain containing protein represses
the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell
proliferation during HCV infection. Cancer Lett. 371:107–116. 2016.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Chiu YH, Lee JY and Cantley LC: BRD7, a
tumor suppressor, interacts with p85α and regulates PI3K activity.
Mol Cell. 54:193–202. 2014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Liu Y, Zhao R, Wei Y, Li M, Wang H, Niu W,
Zhou Y, Qiu Y, Fan S, Zhan Y, et al: BRD7 expression and c-Myc
activation forms a double-negative feedback loop that controls the
cell proliferation and tumor growth of nasopharyngeal carcinoma by
targeting oncogenic miR-141. J Exp Clin Cancer Res. 37:642018.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhao R, Liu Y, Wang H, Yang J, Niu W, Fan
S, Xiong W, Ma J, Li X, Phillips JB, et al: BRD7 plays an
anti-inflammatory role during early acute inflammation by
inhibiting activation of the NF-κB signaling pathway. Cell Mol
Immunol. 14:830–841. 2017. View Article : Google Scholar : PubMed/NCBI
|
13
|
Wang H, Zhao R, Guo C, Jiang S, Yang J, Xu
Y, Liu Y, Fan L, Xiong W, Ma J, et al: Knockout of BRD7 results in
impaired spermatogenesis and male infertility. Sci Rep.
6:217762016. View Article : Google Scholar : PubMed/NCBI
|
14
|
Burrows AE, Smogorzewska A and Elledge SJ:
Polybromo-associated BRG1-associated factor components BRD7 and
BAF180 are critical regulators of p53 required for induction of
replicative senescence. Proc Natl Acad Sci USA. 107:14280–14285.
2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Drost J, Mantovani F, Tocco F, Elkon R,
Comel A, Holstege H, Kerkhoven R, Jonkers J, Voorhoeve PM, Agami R,
et al: BRD7 is a candidate tumour suppressor gene required
for p53 function. Nat Cell Biol. 12:380–389. 2010. View Article : Google Scholar : PubMed/NCBI
|
16
|
Harte MT, O'Brien GJ, Ryan NM, Gorski JJ,
Savage KI, Crawford NT, Mullan PB and Harkin DP: BRD7, a subunit of
SWI/SNF complexes, binds directly to BRCA1 and regulates
BRCA1-dependent transcription. Cancer Res. 70:2538–2547. 2010.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Matissek KJ, Okal A, Mossalam M and Lim
CS: Delivery of a monomeric p53 subdomain with mitochondrial
targeting signals from pro-apoptotic Bak or Bax. Pharm Res.
31:2503–2515. 2014. View Article : Google Scholar : PubMed/NCBI
|
18
|
Wang J, Guo W, Zhou H, Luo N, Nie C, Zhao
X, Yuan Z, Liu X and Wei Y: Mitochondrial p53 phosphorylation
induces Bak-mediated and caspase-independent cell death.
Oncotarget. 6:17192–17205. 2015.PubMed/NCBI
|
19
|
Nieminen AI, Eskelinen VM, Haikala HM,
Tervonen TA, Yan Y, Partanen JI and Klefström J: Myc-induced
AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial
apoptosis. Proc Natl Acad Sci USA. 110:E1839–E1848. 2013.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Xu K, Xiong W, Zhou M, Wang H, Yang J, Li
X, Chen P, Liao Q, Deng H, Li X, et al: Integrating ChIP-sequencing
and digital gene expression profiling to identify BRD7 downstream
genes and construct their regulating network. Mol Cell Biochem.
411:57–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
22
|
Shapter FM and Waters DL: Genome walking.
Methods Mol Biol 1099. 133–146. 2014. View Article : Google Scholar
|
23
|
Liu H, Zhou M, Luo X, Zhang L, Niu Z, Peng
C, Ma J, Peng S, Zhou H, Xiang B, et al: Transcriptional regulation
of BRD7 expression by Sp1 and c-Myc. BMC Mol Biol. 9:1112008.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi
Y, Xiong W, Li G, Lu J, Fodstad O, et al: MicroRNA-125b confers the
resistance of breast cancer cells to paclitaxel through suppression
of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J
Biol Chem. 285:21496–21507. 2010. View Article : Google Scholar : PubMed/NCBI
|
25
|
Luo Y, Wang X, Niu W, Wang H, Wen Q, Fan
S, Zhao R, Li Z, Xiong W, Peng S, et al: Elevated microRNA-125b
levels predict a worse prognosis in HER2-positive breast cancer
patients. Oncol Lett. 13:867–874. 2017. View Article : Google Scholar : PubMed/NCBI
|
26
|
Iida K, Fukushi J, Matsumoto Y, Oda Y,
Takahashi Y, Fujiwara T, Fujiwara-Okada Y, Hatano M, Nabashima A,
Kamura S, et al: miR-125b develops chemoresistance in Ewing
sarcoma/primitive neuroectodermal tumor. Cancer Cell Int.
13:212013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Dai Y, Jin S, Li X and Wang D: The
involvement of Bcl-2 family proteins in AKT-regulated cell survival
in cisplatin resistant epithelial ovarian cancer. Oncotarget.
8:1354–1368. 2017.PubMed/NCBI
|
28
|
Ma J, Zhao Z, Wu K, Xu Z and Liu K: MCL-1
is the key target of adjuvant chemotherapy to reverse the
cisplatin-resistance in NSCLC. Gene. 587:147–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
29
|
Kubo T, Kawano Y, Himuro N, Sugita S, Sato
Y, Ishikawa K, Takada K, Murase K, Miyanishi K, Sato T, et al: BAK
is a predictive and prognostic biomarker for the therapeutic effect
of docetaxel treatment in patients with advanced gastric cancer.
Gastric Cancer. 19:827–838. 2016. View Article : Google Scholar : PubMed/NCBI
|
30
|
Dai H, Ding H, Meng XW, Peterson KL,
Schneider PA, Karp JE and Kaufmann SH: Constitutive BAK activation
as a determinant of drug sensitivity in malignant
lymphohematopoietic cells. Genes Dev. 29:2140–2152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Xiang J, Wang Z, Liu Q, Li X, Sun J, Fung
KP and Liu F: DMFC
(3,5-dimethyl-7H-furo[3,2-g]chromen-7-one) regulates Bim
to trigger Bax and Bak activation to suppress drug-resistant human
hepatoma. Apoptosis. 22:381–392. 2017. View Article : Google Scholar : PubMed/NCBI
|
32
|
Sehrawat A, Kim SH, Hahm ER, Arlotti JA,
Eiseman J, Shiva SS, Rigatti LH and Singh SV: Cancer-selective
death of human breast cancer cells by leelamine is mediated by bax
and bak activation. Mol Carcinog. 56:337–348. 2017. View Article : Google Scholar : PubMed/NCBI
|
33
|
Liguori L, Pastorino F, Rousset X, Alfano
S, Cortes S, Emionite L, Daga A and Ponzoni M: Anti-tumor effects
of Bak-proteoliposomes against glioblastoma. Molecules.
20:15893–15909. 2015. View Article : Google Scholar : PubMed/NCBI
|
34
|
Gao Y, Wang B and Gao S: BRD7 Acts as a
tumor suppressor gene in lung adenocarcinoma. PLoS One.
11:e1567012016.
|
35
|
Li D, Yang Y, Zhu G, Liu X, Zhao M, Li X
and Yang Q: MicroRNA-410 promotes cell proliferation by targeting
BRD7 in non-small cell lung cancer. FEBS Lett. 589:2218–2223. 2015.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Niu W, Luo Y, Wang X, Zhou Y, Li H, Wang
H, Fu Y, Liu S, Yin S, Li J, et al: BRD7 inhibits the Warburg
effect and tumor progression through inactivation of HIF1α/LDHA
axis in breast cancer. Cell Death Dis. 9:5192018. View Article : Google Scholar : PubMed/NCBI
|
37
|
Golick L, Han Y, Kim Y and Park SW: BRD7
regulates the insulin-signaling pathway by increasing
phosphorylation of GSK3β. Cell Mol Life Sci. 75:1857–1869. 2018.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Park SW, Herrema H, Salazar M, Cakir I,
Cabi S, Basibuyuk Sahin F, Chiu YH, Cantley LC and Ozcan U: BRD7
regulates XBP1s' activity and glucose homeostasis through its
interaction with the regulatory subunits of PI3K. Cell Metab.
20:73–84. 2014. View Article : Google Scholar : PubMed/NCBI
|
39
|
Huang L, Li A, Liao G, Yang F, Yang J,
Chen X and Jiang X: Curcumol triggers apoptosis of p53 mutant
triple-negative human breast cancer MDA-MB 231 cells via activation
of p73 and PUMA. Oncol Lett. 14:1080–1088. 2017. View Article : Google Scholar : PubMed/NCBI
|
40
|
Bean GR, Ganesan YT, Dong Y, Takeda S, Liu
H, Chan PM, Huang Y, Chodosh LA, Zambetti GP, Hsieh JJ, et al: PUMA
and BIM are required for oncogene inactivation-induced apoptosis.
Sci Signal. 6:ra202013. View Article : Google Scholar : PubMed/NCBI
|
41
|
Rahmani M, Aust MM, Attkisson E, Williams
DJ Jr, Ferreira-Gonzalez A and Grant S: Dual inhibition of Bcl-2
and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in
human myeloid leukemia cells through a GSK3- and Bim-dependent
mechanism. Cancer Res. 73:1340–1351. 2013. View Article : Google Scholar : PubMed/NCBI
|
42
|
Zhang J, Huang K, O'Neill KL, Pang X and
Luo X: Bax/Bak activation in the absence of Bid, Bim, Puma, and
p53. Cell Death Dis. 7:e22662016. View Article : Google Scholar : PubMed/NCBI
|
43
|
Ren D, Tu HC, Kim H, Wang GX, Bean GR,
Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ and Cheng EH: BID,
BIM, and PUMA are essential for activation of the BAX- and
BAK-dependent cell death program. Science. 330:1390–1393. 2010.
View Article : Google Scholar : PubMed/NCBI
|
44
|
Jones NA, Turner J, McIlwrath AJ, Brown R
and Dive C: Cisplatin- and paclitaxel-induced apoptosis of ovarian
carcinoma cells and the relationship between bax and bak
up-regulation and the functional status of p53. Mol Pharmacol.
53:819–826. 1998.PubMed/NCBI
|